Gavo-cel received FDA orphan drug designation for cholangiocarcinoma
- New DNA Repair Approach Successfully Repairs Pathogenic Gene Mutations in Patients’ Kidney Cells
- Why does moderate starvation during sickness can enhance the activity of immune cells?
- WHO experts agree on new name for monkeypox virus variant
- How terrible is the newly discovered “Langya virus” in China?
- ‘Most Expensive Drug’ Zolgensma facing new challenge after Two Children Died
- Hair loss and sexual dysfunction added to list of symptoms of long-COVID along with fatigue and brain fog
Gavo-cel received FDA orphan drug designation for cholangiocarcinoma
- A highly infectious disease that has been extinct for more than 40 years has appeared in New York
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Omicron new variant BA.2.75 has stronger infectivity than BA.4 and BA.5?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Gavo-cel received FDA orphan drug designation for cholangiocarcinoma.
On September 2, 2021, TCR2 Therapeutics Inc. announced that the US Food and Drug Administration (FDA) has granted Gavocabtagene autoleucel (gavo-cel; TC-210) Orphan Drug Designation (ODD) for the treatment of cholangiocarcinoma .
Gavo-cel is a new type of cell therapy consisting of autologous genetically engineered T cells expressing a single domain antibody that recognizes human mesothelin and is fused to the CD3-ε subunit, which is integrated into the endogenous after expression Sex T cell receptor (TCR) complex.
The new clinical data from the dose escalation part of the Phase 1/2 clinical trial of Gavo-cel for the treatment of patients with refractory mesothelin-expressing solid tumors will be highlighted as part of the oral report of the 2021 ESMO conference. The study will include Gavo-cel in Data in malignant mesothelioma, ovarian cancer, and cholangiocarcinoma. At that time, Tumor Jun will also bring readers the sharing of the latest data.
(Picture from ESMO official website)
(The picture is from the official website of TCR2)
Solid tumors expressing mesothelin
Mesothelin is a cell surface glycoprotein that is highly expressed in a variety of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, and pancreatic cancer. Since mesothelin plays an active role in malignant transformation and tumor invasion by promoting the proliferation, invasion and metastasis of cancer cells, the overexpression of mesothelin is related to the poor prognosis of certain cancers. In the United States alone, among various solid tumors expressing mesothelin, non-small cell lung cancer, ovarian cancer, mesothelioma and cholangiocarcinoma have as many as 80,000 patients each year.
(source:internet, reference only)
Disclaimer of medicaltrend.org
